Revealed: In Vivo's 2024 Rising Leaders
30 people to watch from across the life sciences sector
VIEW NOWIn Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Printed By
A recent analysis from Biomedtracker of clinical trial phase transitions between 2014 and 2023 suggests biopharma development success rates are falling. This poses several questions: what are the underlying reasons dragging success rates down and what does this mean for R&D productivity and the return on investment on pipeline spend?
With big pharma on a radiopharmaceuticals buying spree, New York-based Actinium Pharmaceuticals has been pointed to as the next potential takeout target.
Estonia is hoping to create a brighter future by attracting leading startups to its borders, a process that will bring tax revenues, jobs and infrastructure.
Estonia is hoping to create a brighter future by attracting leading startups to its borders, a process that will bring tax revenues, jobs and infrastructure.
BioBytes presents an overview of AI-related deals in Q1 2024. This is the first in a recurring series of quarterly deal updates.
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
With a reliable source of revenue in Arikayce and two key pulmonary late-stage trials reading out, Insmed aims to keep its commercial momentum going.
AlphaFold 3 is promising, but for now it stays in the hands of Isomorphic Labs and its partners.
Breathomics, UTI diagnosis and advanced wound healing innovations were among the center stage technologies at BioWales in London 2024.
Having raised $345m in an IPO last year, prior to entering the clinic, Apogee Therapeutics has emerged as a startup to watch. Chief medical officer Carl Dambkowski, one of In Vivo’s 2024 Rising Leaders, shares more about the biotech’s pipeline strategy.
Laura Soucek, a former In Vivo Rising Leader, and her co-founder have built their biotech, Peptomyc, around a previously undruggable target. They spoke about successes and learnings as scientist-entrepreneurs at BioEurope Spring.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Rising star Agnė Vaitkevičienė is juggling roles as the CEO of an emerging Lithuanian biotech, with work for a partner company, the national biotech trade association and much more.
AI Medical Technology has been busy, with publications demonstrating its lead product’s potential in melanoma, ongoing fundraising and board appointments.
Addex Therapeutics’ Tim Dyer has seen the company through 22 years of ups and downs. He has kept the company afloat, and recently did the same by spinning out a new company.
With the passage of the Inflation Reduction Act, many have questioned whether Medicare price negotiations will stifle small molecule innovation.
The FTC is intensifying its crackdown on pharmaceutical companies' misuse of patent listings as industry seeks clearer guidelines.
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve access to lifesaving therapies. Payers and politicians must be persuaded to loosen their purse strings – and open their minds.
Wales must be better at adoption, said Mike Emery, the Welsh government’s digital and innovation officer for health and social care, in conversation with In Vivo.
Seven $1bn+ alliances were penned in April. In the top alliance by deal value, Medincell entered a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications. Medincell will receive a $35m upfront payment and is eligible to receive up to $1.9bn in development and commercial milestones, plus mid-single to low-double-digit royalties on net sales.
With big pharma on a radiopharmaceuticals buying spree, New York-based Actinium Pharmaceuticals has been pointed to as the next potential takeout target.
A recent analysis from Biomedtracker of clinical trial phase transitions between 2014 and 2023 suggests biopharma development success rates are falling. This poses several questions: what are the underlying reasons dragging success rates down and what does this mean for R&D productivity and the return on investment on pipeline spend?
An interactive look at pharma, medtech and diagnostics deals made during April 2024. Data courtesy of Biomedtracker.
AlphaFold 3 is promising, but for now it stays in the hands of Isomorphic Labs and its partners.
Seven $1bn+ alliances were penned in April. In the top alliance by deal value, Medincell entered a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications. Medincell will receive a $35m upfront payment and is eligible to receive up to $1.9bn in development and commercial milestones, plus mid-single to low-double-digit royalties on net sales.
A recent analysis from Biomedtracker of clinical trial phase transitions between 2014 and 2023 suggests biopharma development success rates are falling. This poses several questions: what are the underlying reasons dragging success rates down and what does this mean for R&D productivity and the return on investment on pipeline spend?
With the passage of the Inflation Reduction Act, many have questioned whether Medicare price negotiations will stifle small molecule innovation.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Rising star Agnė Vaitkevičienė is juggling roles as the CEO of an emerging Lithuanian biotech, with work for a partner company, the national biotech trade association and much more.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
AI Medical Technology has been busy, with publications demonstrating its lead product’s potential in melanoma, ongoing fundraising and board appointments.
Breathomics, UTI diagnosis and advanced wound healing innovations were among the center stage technologies at BioWales in London 2024.
An interactive look at pharma, medtech and diagnostics deals made during April 2024. Data courtesy of Biomedtracker.
Having raised $345m in an IPO last year, prior to entering the clinic, Apogee Therapeutics has emerged as a startup to watch. Chief medical officer Carl Dambkowski, one of In Vivo’s 2024 Rising Leaders, shares more about the biotech’s pipeline strategy.
Laura Soucek, a former In Vivo Rising Leader, and her co-founder have built their biotech, Peptomyc, around a previously undruggable target. They spoke about successes and learnings as scientist-entrepreneurs at BioEurope Spring.
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.